Join the campaign now!

If you are tired of suffering from herpes simplex and you wish for real solutions, 

the first step is to ask for help.

You can send letters.

You can anonymously sign the petition

or you can do both.

It is all up to you!

A Penny For Your Thoughts, The letter campaign

I've made it easy to ask for help. Just print the letter, sign and tape a penny to the bottom.

 With the recent studies making the possible direct connect to Alzheimer’s  due to (Herpes simplex) HSV1, HHV6 and HHV7, and the 2 to 3 fold  increased risk factor of contracting HIV due to (Herpes simplex) HSV2, it is now more important than ever to ask for help. 


 The Penny for your thoughts campaign is a great opportunity that allows you to ask for help and to give you a voice. A voice for yourself or for others who are suffering silently. This effort does not exclude people who are doing just fine and are not affected by the herpes virus, we need your help as well!

 

 I have created a form letter that can be easily printed and addressed to your own local Congressman or Senator, asking for help with Herpes research and asking to fast track the study of the Herpes vaccine,  RVX101 and RVX201. This will help the proper representatives understand that we need help now, rather than waiting the customary 15 years. 


 Simply click below to download the letter, print, address your proper representative, sign and mail. But before you mail it, I ask that you tape a penny at the bottom of the letter. The reason for this is because any money that is received, they must account for. This will ensure that your letter gets the proper attention. :)


Dear  Congressman/Congresswoman/Senator, 

     

     

The reason for my letter is to ask you for help and this is not for something that is very common. I am asking for help towards Herpes research and to fast track a particular vaccine study. 


 For many individuals (80% of people who are infected), Herpes is not a big deal and they are doing just fine; or are completely unaware. (This is due to the lack of proper testing). However, to the 20% of the approximate 5 billion people world wide {1} who are Herpes positive, many succumb to this infection and suffer in often debilitating ways. Many suffer from severe neuralgic pain, outbreaks, (blisters, ulcers), unforeseen side effects, and for many of these people antiviral medication simply does not work. Many people are unaware of the suicide rate within the Herpes communities because it is never talked about in public. These are the millions who suffer in silence. Your sister, your brother, your partner, or even your parents who never said a word. Wouldn’t it be great to make these people healthier and more productive, instead of suffering? 


 This concern of Herpes has also increased due to research on two very important diseases, HIV and Alzheimer’s. The risk factor for HIV {2} in individuals with herpes simplex who are positive with HSV2, increases 2- to 3-fold. This is not only substantial, it is very troubling. There is also the growing concern over the new research on the subject of Alzheimer’s {3} and its possible causation directly from herpes HSV-1 (commonly known as cold sores), HHV-6 (Roseola), {4} and HHV-7. {5} 


“Many scientists believe that HSV1 is a major contributory factor for Alzheimer’s disease and 

that it enters the brains of elderly people as their immune system declines with age. It then establishes a latent (dormant) infection, from which it is reactivated by events such as stress, a reduced immune system and brain inflammation induced by infection by other microbes. Reactivation leads to direct viral damage in infected cells and to viral-induced inflammation. We suggest that repeated activation causes cumulative damage, leading eventually to Alzheimer’s disease in people with the APOE4 gene. Presumably, in APOE4 carriers, Alzheimer’s disease develops in the brain because of greater HSV1-induced formation of toxic products, or less repair of damage.” {6} 


Unknown to most, there is also the unfortunate Herpes infection that happens to infants. They are born and exposed to the Herpes simplex virus either through the birth canal or infected from a simple kiss from a relative or loved one. This is known as Neonatal Herpes. {7} Globally there are over 14,000 (and growing), new cases each year. All of this information is a game changer and all the more reasons we ask for help. Many diseases are vaccine preventable including Chicken pox, Herpes simplex should be the next logical step forward. The past 30 years of vaccine trials {8} have failed or have at least failed to elicit results that are better than taking antivirals, this is a very sad state of affairs. We are simply asking for more help from the NIH and the FDA towards therapeutic and preventable vaccines. 

 

 One vaccine in particular called Theravax, (now called RVX-101 and RVX-201), was in the news in 2016 {9} and got some bad press. However, this doesn’t change the fact that it helped some people {10} get much better and it showed great promise—much better than previous vaccine trials. 


 Hopefully, one day soon, the company working on the vaccine (Rational Vaccines), will be running new trials under the jurisdiction of the FDA. There is also a petition that has begun and is asking the FDA Director, Janet Woodcock, M.D. (Center for Drug Evaluation & Research), for help as well. {11} 


 I am asking for help—from you, to push for more funding towards herpes research, and to please contact the FDA and ask them to fast track the study of the vaccine so that it can possibly move faster into FDA trials. This would also benefit many people who are suffering and give them hope so that they do not have to wait the customary 10 to 15 year time period, and suffer any further. 


Please send this request to 

Dr. Peter Marks M.D. PhD
Center for Biologics Evaluation and Research U.S. Food and Drug Administration
10903 New Hampshire Avenue
WO71-7232
Silver Spring, MD 20993 

Peter.Marks@fda.hhs.gov 1-240-402-8116 


Sincerely yours, 

image4

How easy is it to send a letter?

instructions

1. Download the letter

In the next section below, click on the download button and the PDF will show up in a new window.

2. Print the letter

Depending on your computer, you should have a print option. Click on print, you will see 4 pages.

3. Address the letter

The Greeting of the letter is intentionally left blank. This is so you may send each letter to a separate individual. It would be ideal to send the letter to Congress and the Senate, but you are not confined to sending to only two places. Send it to any person that you think may be helpful. Someone famous? A TV show? The options are endless, it's all about awareness....

4. Don't forget to sign your name

There is a space at the bottom to sign your name.

5. Tape a penny near your signature

If you have a penny, tape it to your letter. If you don't, it's OK as well.

6. Address your envelope and mail it

Pretty easy right?

Download Campaign letter

I did most of the work for you. All you need to do is download the letter, find the

 correct name, corresponding address, sign the letter and mail it. Oh, but don't forget the penny!

PDF Letter 8:19 (pdf)

Download

Where do I send my letter and who gets it?

That's an easy answer. Just click below.

After printing the letter you will need to address it to your proper representative.

Find your local Congressman or Congresswoman

image5

Find your local Congressman/Congresswoman by State

Click Here

Find your local Senator

image6

Find your local Senator by State 

Click here

State by State Directory

Directory of U.S. Congress 2019

image7

A complete list of all U.S. Congressman and Congresswomen

Click here

Directory of U.S. Senators 2019

image8

A complete list of all U.S. Senators

Click here

want to send a letter/email to the National institute of health?

NIH. The National Institute of Health

The National Institutes of Health (NIH), a part of the U.S. Department  of Health and Human Services, is the nation’s medical research agency —  making important discoveries that improve health and save lives. 

To email your letter or for general inquires; 

ocpostoffice@niaid.nih.gov

Contact

Contact The House Committee on Science

Chair member Eddie Bernice Johnson

image9

https://ebjohnson.house.gov/

2306 Rayburn Office Building Washington, DC 20515 

phone: (202) 225-8885
fax: (202) 226-1477

Vice Chair Dr. Ami Bera

image10

https://bera.house.gov/

https://bera.house.gov/connect-with-me/email-ami

1727 Longworth House Office Building Washington, DC 20515 

Phone: (202) 225-5716
Fax: (202) 226-1298

Ranking Member Rep Frank Lucas

image11

https://lucas.house.gov/

https://lucas.house.gov/contact-me/email-me

Washington, DC Office 

2405 Rayburn HOB Washington, DC 20515
Phone: (202) 225-5565
Fax: (202) 225-8698

GoFundMe

Please support the campaign. 

Even a small donation will help support the website and advertising costs.

GoFundMe
image30

{8}

The glycoprotein subunit vaccine approach of the mid-1980s finally made  its way to efficacy (effectiveness) trials in the 1990s, and now it was  time to find out if immunization with gB- and/or gD-based vaccines either (1) reduced the symptoms of genital herpes in those already  infected with HSV-2 or (2) protected naive individuals from acquiring  HSV-2 genital herpes for a period of 2 to 5 years after vaccination. On both counts, gB- and/or gD-based subunit vaccines were a  disappointment.
 
Vaccination with gB- and/or gD-vaccines elicited a strong antibody  (immune) response against the HSV-2 proteins contained in the vaccine  itself, but this immune response did not render vaccine recipients any  better off in their ability to fight off infection with the actual HSV-2  virus. In particular, the gB- and/or gD-based vaccine failures of the 1990s may be found in the following four research publications:
 
1990. Double-blind, placebo-controlled trial of a herpes simplex virus  type 2 glycoprotein vaccine in persons at high risk for genital herpes  infection. Mertz GJ, Ashley R, Burke RL, Benedetti J, Critchlow C, Jones CC, Corey L.  J Infect Dis. 1990 Apr;161(4):653-60.https://www.ncbi.nlm.nih.gov/pubmed/2181031
1994. Placebo-controlled trial of vaccination with recombinant  glycoprotein D of herpes simplex virus type 2 for immunotherapy of  genital herpes. Straus SE, Corey L, Burke RL, Savarese B, Barnum G,  Krause PR, Kost RG, Meier JL, Sekulovich R, Adair SF, et al. Lancet. 1994 Jun 11;343(8911):1460-3.
https://www.ncbi.nlm.nih.gov/pubmed/7911177
1997. Immunotherapy of recurrent genital herpes with recombinant herpes  simplex virus type 2 glycoproteins D and B: results of a  placebo-controlled vaccine trial.  Straus SE, Wald A, Kost RG, McKenzie  R, Langenberg AG, Hohman P, Lekstrom J, Cox E, Nakamura M, Sekulovich R,  Izu A, Dekker C, Corey L.  J Infect Dis. 1997 Nov;176(5):1129-34.
https://www.ncbi.nlm.nih.gov/pubmed/9359709
1999.  Recombinant glycoprotein vaccine for the prevention of genital  HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine  Study Group.  Corey L, Langenberg AG, Ashley R, Sekulovich RE, Izu AE,  Douglas JM Jr, Handsfield HH, Warren T, Marr L, Tyring S, DiCarlo R,  Adimora AA, Leone P, Dekker CL, Burke RL, Leong WP, Straus SE.  JAMA.  1999 Jul 28;282(4):331-40.
 https://www.ncbi.nlm.nih.gov/pubmed/10432030